APPLICATIONS
for EPILEPTIC, COGNITIVE
AND MOVEMENT DISORDERS

At SynapCell, our mission is to identify and qualify the therapeutic potential of your molecules. We reveal this potential, using EEG markers of CNS pathologies, for which we have established relevant standards.

You will be able to compare your molecule to the ones on the market and demonstrate its superiority.

Epileptic
DISORDERS

An epileptic disorder is a chronic neurological condition characterized by recurrent epileptic seizures. Epileptic seizures are characterized by a hypersynchrony and hyperexcitability of one, or several, neural networks, leading to the appearance of spontaneous epileptiform events, recorded by EEG (spikes, discharges etc…). These events can be used as translational EEG biomarkers for drug discovery.

Applications: Epilepsies, Autism spectrum disorders (ASD), Alzheimer’s disease

Markers: Spikes, Hippocampal Paroxysmal Discharges (HPD), Spike and wave discharge (SWD)

Models: MTLE mouse (a mouse model for mesiotemporal lobe epilepsy with differential pharmacology), GAERS (a rat model of epilepsy absence to test for antiepileptic or proepileptic effect of candidate drugs)

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, antiepileptogenic effect, rodent model phenotyping, derisking (pro-epileptic effect)

Cognitive
DISORDERS

Cognitive disorders involve disturbances in information processing associated with cognitive impairment and/or progressive cognitive decline. These disorders can be studied using translational EEG biomarkers and can be accurately targeted for drug discovery.

Applications: Autism spectrum disorders (ASD), Schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy

Markers: ERPs, EROs, MMN, Gating, Multisite Coherence

Models: NMDA antagonists, Scopolamine. For other models, please contact us.

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping

Movement
DISORDERS

Movement disorders are a group of diseases and syndromes affecting a patient’s ability to produce and control movement of their body parts. These disorders represent a class of neurological conditions affecting the overall quality, speed and fluency of movement. Several movement alterations correlate with modifications to EEG activities. For example, in Parkinson’s disease, antikinetic and prokinetic oscillatory activities in the beta and gamma frequency bands are prominent. These activities can therefore be used as surrogate EEG biomarkers for drug discovery.

Applications: Parkinson’s disease, Huntington’s disease, essential tremor, dyskinesia

Markers: beta and gamma oscillations, Multisite coherence

Models: 6-OHDA lesioned rats or contact us

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, rodent model phenotyping